BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model[1].
Target:
Transmembrane Glycoprotein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
